Drugs / TECOTABART
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04735796 | May 2021 → May 2022 | cancer | LaNova Medicines Limited | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05008445 | Oct 2021 → Feb 2023 | neoplasm | LaNova Medicines Development Co., Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TECOTABART | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068179 ↗ |
| Known as | LM-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05008445 ↗ |
| Modality | Monoclonal antibody | “a recombinant humanized monoclonal antibody” NCT05008445 ↗ |
| Route | Intravenous | “intravenous (IV) infusion” NCT04735796 ↗ |
| Target | CLDN18 | “targeting Claudin 18.2 (CLDN18.2)” NCT05008445 ↗ |